We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
From May 2021 to May 2024
By Dave Sebastian
Merck & Co. Inc. said the European Commission has approved its Keytruda drug in combination with chemotherapy for the treatment of certain patients with esophageal cancer.
The approval lets the company market the Keytruda combination in all 27 European Union member states, as well as Iceland, Lichtenstein, Norway and Northern Ireland, Merck said Tuesday.
Merck said the approval is based on a Phase 3 trial in which a Keytruda combination demonstrated improvements in overall survival and progression-free survival.
The company said it is continuing to study Keytruda in multiple settings and stages of gastrointestinal cancer, including studies in esophageal, gastric, hepatobiliary, pancreatic, colorectal and anal cancers.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
June 29, 2021 07:14 ET (11:14 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
